In the past few decades, clinical trials and studies have shown that PD-1/PD-L1 inhibitors significantly improve the survival rate of patients with advanced non-small-cell lung cancer (NSCLC)1–4. This evidence concerns the gene CD274 and non-small cell lung carcinoma.